trimethyl[2-({4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl}oxy)ethyl]azanium

• ChemBase编号: 87
• 分子式: C14H30N2O4++
• 平均质量: 290.399
• 单一同位素质量: 290.22055745
• SMILES: O(CC[N+](C)(C)C)C(=O)CCC(=O)OCC[N+](C)(C)C
• Canonical SMILES: O=C(OCC[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C
• InChI: InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
• InChIKey: AXOIZCJOOAYSMI-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: trimethyl[2-({4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl}oxy)ethyl]azanium
• IUPAC传统名: succinylcholine
• 商标名: Anectine; Quelicin; Quelicin Preservative Free; Sucostrin
• 别名: Succinylcholine Chloride; Suxamethonium chloride; Scoline; Succinylcholine

登记号

• CAS号: 306-40-1
• PubChem SID: 46506023; 160963550
• PubChem CID: 5314

理论计算性质

JChem

• 质子受体: 2
• 质子供体: 0
• LogD (pH = 5.5): -8.394079
• LogD (pH = 7.4): -8.394079
• Log P: -8.394079
• 摩尔折射率: 100.9406 cm^3
• 极化性: 31.004166 Å^3
• 极化表面积: 52.6 Å^2
• 可自由旋转的化学键: 11
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: -2.49
• LOG S: -5.68
• 溶解度: 7.57e-04 g/l

详细说明

DrugBank - DB00202

• Drug Groups: approved
• Description: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for. [PubChem]
• Indication: Used in surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ECT)
• Pharmacology: Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine is a depolarizing skeletal muscle relaxant. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the receptor site. Succinylcholine has no direct action on the uterus or other smooth muscle structures.
• Affected Organisms: Humans and other mammals
• Biotransformation: By pseudocholinesterase, to succinylmonocholine and choline.
• Elimination: About 10% of the drug is excreted unchanged in the urine.
• References: Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33. Pubmed